Company News-Bio-Thera Solutions, Ltd.

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

2026-02-13

• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...

查看详情

10-152022

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab)

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177),a commercial-stage biopharmaceutical company, ...
10-152022

Bio-Thera Solutions Announces Details of Poster Presentation of a Highly Thermal Stable Recombinant Bivalent Nanoparticle Vaccine Containing Spikes of SARS-CoV-2 Omicron and Delta at Vaccine Summit 20

Guangzhou,China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), acommercial-stage biopharmaceutical company, ...
10-152022

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Advanced Solid Tumors

FRα is a folicacid-binding protein located on cell membranes that is overexpressed in avariety of solid tumors such as o...

上一页 ···17 18 19 20 21 ··· 下一页